Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Concert Pharmaceuticals Inc    CNCE

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/15/2017 11/16/2017 11/17/2017 11/20/2017 11/21/2017 Date
19.9(c) 20.91(c) 20.67(c) 21.25(c) 22.12 Last
502 966 657 516 384 640 426 623 288 289 Volume
+6.65% +5.08% -1.15% +2.81% +4.09% Change
More quotes
Financials ($)
Sales 2017 149 M
EBIT 2017 96,7 M
Net income 2017 94,2 M
Finance 2017 169 M
Yield 2017 -
Sales 2018 7,36 M
EBIT 2018 -61,9 M
Net income 2018 -61,3 M
Finance 2018 93,7 M
Yield 2018 -
P/E ratio 2017 5,31
P/E ratio 2018
EV / Sales2017 2,11x
EV / Sales2018 53,0x
Capitalization 484 M
More Financials
Company
Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs for renal disease, CNS disorders, inflammation and hematologic disorders.It also creates novel medicines that address commercially important needs by applying its... 
More about the company
Surperformance© ratings of Concert Pharmaceuticals In
Trading Rating : Investor Rating :
More Ratings
Latest news on CONCERT PHARMACEUTICALS IN
11/16 CONCERT PHARMACEUTICALS : Announces Completion of Enrollment in First Cohort of ..
11/14 Concert Pharmaceuticals Reports Third Quarter 2017 Financial Results and Prov..
11/09 CONCERT PHARMACEUTICALS : posts 3Q profit
11/09 CONCERT PHARMACEUTICALS INC : Concert Pharmaceuticals, Inc. to Host Earnings Cal..
11/09 CONCERT PHARMACEUTICALS : Management's Discussion and Analysis of Financial Cond..
11/09 CONCERT PHARMACEUTICALS, INC. : Results of Operations and Financial Condition (f..
11/09 CONCERT PHARMACEUTICALS : Reports Third Quarter 2017 Financial Results and Provi..
11/09 CONCERT PHARMACEUTICALS : Announces Completion of Enrollment in First Cohort of ..
11/07 CONCERT PHARMACEUTICALS : to Report Third Quarter 2017 Financial Results on Nove..
11/06 CONCERT PHARMACEUTICALS : Announces Completion of Enrollment in First Cohort of ..
More news
Sector news : Biotechnology & Medical Research - NEC
11/16 Recovery rally for European stocks leaves oil sector behind
11/13 Poor earnings updates keep European shares at seven-week low
11/13DJNOVARTIS : Vision Drug Shows Positive Results in Phase 3 Trials
11/03 Prosecutors search Metro offices in insider trading probe
11/01DJAs Experimental Treatments Grow, Families Face Tough Choices
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
11/17 Concert Pharma (CNCE) Presents At Jefferies 2017 London Healthcare Conference..
11/09 Concert Pharmaceuticals' (CNCE) CEO Roger Tung on Q3 2017 Results - Earnings ..
11/09 Concert Pharma EPS of $5.44
10/26 Premarket analyst action - healthcare
10/25 DAILY INSIDER RATINGS ROUND UP 10/23 : Zyne, plse, fldm, tts, cnce, botj, sxcp
Chart CONCERT PHARMACEUTICALS IN
Duration : Period :
Concert Pharmaceuticals In Technical Analysis Chart | CNCE | US2060221056 | 4-Traders
Technical analysis trends CONCERT PHARMACEUTICALS IN
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 23,8 $
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Roger D. Tung President, Chief Executive Officer & Director
Richard H. Aldrich Chairman
Nancy Stuart Chief Operating Officer
Ryan Lynch Controller, Chief Financial & Accounting Officer
Wilfred E. Jaeger Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CONCERT PHARMACEUTICALS INC100.87%484
CELLTRION, INC.--.--%24 243
IQVIA HOLDINGS INC37.36%21 955
INCYTE CORPORATION5.19%20 882
LONZA GROUP59.15%19 698
ALNYLAM PHARMACEUTICALS, INC.240.57%12 601